Dyne Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapeutics for individuals with genetically driven muscle diseases. Utilizing its proprietary FORCE™ platform, Dyne is working on modern oligonucleotide therapeutics that aim to enhance delivery to muscle tissues, addressing significant challenges in treatment efficacy. The company has an extensive pipeline that includes advanced clinical programs targeting myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), alongside preclinical initiatives for facioscapulohumeral muscular dystrophy (FSHD). Dyne is committed to improving patient outcomes through innovative research and development, ensuring that those affected by rare muscle diseases have access to effective treatments.